68Ga-PSMA-11

Phase 3

Novartis AG (NVS)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Dec '26

NVSPhase 2$271.5B

AAA617 Phase 2 Est. Readout

68Ga-PSMA-11• Metastatic Castration-Resistant Prostate Cancer (mCRPC)23

Dec 2026~Estimated

CT.gov

00%

Competitive Landscape

2 competitors in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

AZNNiraparib plus Abiraterone acetate plus Prednisone

Phase 3

REGNREGN15505+Cemiplimab

Phase 2

View Full Landscape

Drug Information

Target Indication

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Clinical Trial

NCT06004661

Last updated: 5/23/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

NVS

Novartis AG

Pharmaceutical Preparations•Europe•NYSE

Related Pipeline

Peg-alpha interferon (Peg-Intron)Phase 3

Leukemia, Myeloid, Chronic

cyclosporin + mycophenolate mofetilPhase 3

Kidney Failure

Imatinib Mesylate (Gleevec)Phase 3

Idiopathic Pulmonary Fibrosis

GP2017 (adalimumab biosimilar)Phase 3

Ankylosing Spondylitis

Nilotinib (Tasigna ®)Phase 3

Chronic Myeloid Leukemia

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts